We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-14.23%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.99B
AUM Growth
-$1.5B
Cap. Flow
-$539M
Cap. Flow %
-10.81%
Top 10 Hldgs %
44.72%
Holding
159
New
13
Increased
22
Reduced
36
Closed
24

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$47.6M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$33.3M
3
NVRO
NEVRO CORP.
NVRO
+$32.7M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$32.1M
5
PEN icon
Penumbra
PEN
+$31.9M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$104M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$92.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$46.5M
4
KOD icon
Kodiak Sciences
KOD
+$44.1M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$37.1M

Sector Composition

Rank Sector Weight
1 Healthcare 81.81%
2 Financials 0.77%
3 Industrials 0.12%
4 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LONA
26
LeonaBio Inc
LONA
$66.1M
$46.3M 0.93%
342,592
– –
ALDX icon
27
Aldeyra Therapeutics
ALDX
$97.1M
$44M 0.88%
9,903,879
– –
CCXI
28
DELISTED
ChemoCentryx, Inc.
CCXI
$41.5M 0.83%
1,655,079
+239,633
+17% +$6.73M
CINC
29
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$40.7M 0.81%
+2,319,117
New +$47.6M
INBX
30
DELISTED
Inhibrx, Inc. Common Stock
INBX
$39.7M 0.79%
1,781,235
+437,745
+33% +$11.2M
NAUT icon
31
Nautilus Biotechnolgy
NAUT
$132M
$39.5M 0.79%
9,111,151
– –
BBIO icon
32
BridgeBio Pharma
BBIO
$16.4B
$39M 0.78%
3,839,380
-3,289,375
-46% -$33.8M
NBIX icon
33
Neurocrine Biosciences
NBIX
$18.2B
$37.1M 0.74%
395,639
-87,368
-18% -$7.4M
ZYME icon
34
Zymeworks
ZYME
$1.62B
$34.9M 0.7%
5,325,615
+1,645,770
+45% +$14.7M
NVRO
35
DELISTED
NEVRO CORP.
NVRO
$34.5M 0.69%
477,037
+454,091
+1,979% +$32.7M
PEN icon
36
Penumbra
PEN
$12.6B
$31.9M 0.64%
+143,591
New +$31.9M
MORF
37
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$30.8M 0.62%
767,327
-69,194
-8% -$2.9M
ESTA icon
38
Establishment Labs
ESTA
$2.71B
$30.4M 0.61%
450,374
+44,833
+11% +$2.62M
ALNY icon
39
Alnylam Pharmaceuticals
ALNY
$38.3B
$29.4M 0.59%
+180,079
New +$27.4M
VRCA icon
40
Verrica Pharmaceuticals
VRCA
$89M
$29.3M 0.59%
361,041
– –
DICE
41
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$29M 0.58%
1,515,361
+810,476
+115% +$14.5M
MDGL icon
42
Madrigal Pharmaceuticals
MDGL
$12.6B
$27.3M 0.55%
278,286
+191,886
+222% +$16.2M
RCKT icon
43
Rocket Pharmaceuticals
RCKT
$343M
$26.6M 0.53%
1,678,090
-281,035
-14% -$4.86M
VRDN icon
44
Viridian Therapeutics
VRDN
$2.2B
$26.3M 0.53%
1,423,053
– –
NUVL
45
DELISTED
Nuvalent
NUVL
$24.3M 0.49%
1,751,601
+1,001,601
+134% +$14.6M
COGT icon
46
Cogent Biosciences
COGT
$6.76B
$23.9M 0.48%
3,188,750
– –
CMAX
47
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$23.8M 0.48%
106,222
-12,096
-10% -$2.51M
ZNTL icon
48
Zentalis Pharmaceuticals
ZNTL
$332M
$23.1M 0.46%
501,509
+70,965
+16% +$3.83M
OMIC
49
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$23.1M 0.46%
121,840
+10,713
+10% +$2.48M
LEGN icon
50
Legend Biotech
LEGN
$3.65B
$22.4M 0.45%
616,141
+427,041
+226% +$16.9M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Perceptive Advisors held 159 positions worth $4.99B, down 23% from $6.49B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $539M in Q1 2022, closing 24 positions and reducing 36 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $104M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in CinCor Pharma, Inc. Common Stock worth $40.7M.

  • Perceptive Advisors's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 2,319,117 shares worth $40.7M.
  • Perceptive Advisors added most to NEVRO CORP. in Q1 2022, an estimated $32.7M increase.
  • Perceptive Advisors's biggest Q1 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $92.4M.
  • Perceptive Advisors fully exited BioMarin Pharmaceuticals in Q1 2022, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $4.99B portfolio in Q1 2022.
  • Perceptive Advisors opened 13 new positions and closed 24 in Q1 2022.
  • Perceptive Advisors's portfolio value fell 23% quarter-over-quarter to $4.99B.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.